Syneron Bio closed a $150 million Series B to support development of its macrocyclic peptide discovery platform. The company previously raised nearly $100 million and also secured a multi-billion-dollar deal with AstraZeneca, with this new round designed to expand platform output for later-stage pipeline construction. Macrocyclic peptides are positioned as a way to improve binding selectivity and pharmacokinetics versus linear peptides, while also diversifying the modality set in an increasingly competitive drug discovery landscape. Syneron’s funding signals continued investor interest in peptide libraries with clear translation paths. For peers, the event adds competitive pressure in the peptide discovery arms race—particularly against other platform-led entrants seeking to convert screening throughput into clinical candidates.